Biocytogen

🔍 Discover New Insights in IBD Treatment! 🔍 Join us on September 5th at 1:00 PM EST for an exclusive Biocytogen webinar, "Advancing IBD Treatment: Leveraging Innovative Models and Therapies for Enhanced Drug Development." 🎙️ Featuring: Dr. Luo (Jack) Jia, Senior Scientist and Study Director, and Team Lead for Disease Modeling at Biocytogen. 🧪What You'll Learn: A comprehensive overview of the current IBD therapeutic landscape and its challenges. Insights into the use of conventional and targeted humanized mouse models that are transforming IBD research. An exploration of the future of IBD drug discovery and its potential impact on clinical applications. Who Should Attend? Researchers, clinicians, and anyone involved in drug development looking to stay at the forefront of IBD treatment advancements. RSVP for your Zoom link: https://lnkd.in/g_RjWXvS #IBD #DrugDevelopment #Innovation #MedicalResearch #LifeSciences #Biocytogen

🌟Set a reminder for Gene-ius Break in Philadelphia!🌟 Circle the date for Biocytogen and KACTUS's Gene-ius Break— September 11th in Philadelphia! This is your chance to revel in an unforgettable happy hour experience, indulge in delicious complimentary food and drinks, and mingle with top biotech professionals! With spots filling up fast, register soon to guarantee your place. Come and engage, relax, and enjoy the evening. We can’t wait to see you there! 🗓️ Date: Wednesday, September 11 · 5 - 8pm EDT 📍 Location: Pyramid Club. 1735 Market St 52nd floor, Philadelphia, PA 19103 Register here: https://lnkd.in/eNZtU-88 #Biocytogen #HappyHour #Philadelphia #Networking #Innovation #Biotech

🎉Fun Fact with Biocytogen, cast your vote below and find out! 🐭 #LinkedInPoll #MouseHearing #AnimalBehavior #BiologyTrivia #ResearchInsights

🌟 Harnessing the Power of Humanized TGFβ Models for Research 🌟 Transforming growth factor beta (TGF-β) is a key cytokine that regulates immune responses and stem cell differentiation, playing a significant role in cancer and autoimmune diseases. Dysregulation of TGF-β often contributes to malignancies and immune disorders by promoting immunosuppression and disrupting normal cell functions. Biocytogen offers a range of Humanized TGFβ Models that are ideal for evaluating therapeutic candidates for inflammatory diseases and cancer. Our B-hTGFB1 mice are designed to express human TGFβ1, providing valuable insights for preclinical studies. Discover the potential of these models in your research! Contact us today to learn more about our models, data packages, and licensing opportunities. #Biocytogen #CancerResearch #TGFβ #Immunotherapy #AutoimmuneDisease 

🌟 Immerse yourself at the Gene-ius Break Forum in South SF!🌟 Come and discover what’s next in biotech at the Gene-ius Break Forum in South San Francisco on September 25th! This one-of-a-kind event features thought-provoking speeches, delicious complimentary food and drinks, and unparalleled networking opportunities. These dynamic presentations will add exceptional value to the evening. After the talks, enjoy great food and drinks while connecting with industry leaders. Catch this unique night of inspiration and innovation! Limited spots available—RSVP today! 🗓️ Date: Wednesday, September 25th · 4pm - 8pm PDT 📍 Location: Tower Place, 1 Tower Pl, South San Francisco, CA 94080 RSVP here: https://lnkd.in/eWHbVtwS #Biocytogen #HappyHour #SouthSF #Networking #Innovation #Biotech

🚀 Addressing Unmet Needs in NSCLC: Biocytogen's Innovative Approach to Combating Resistance and Enhancing Immunotherapy 🚀 Lung cancer remains the leading cause of cancer-related deaths worldwide, taking an estimated 1.8 million lives annually. Among these cases, Non-Small Cell Lung Cancer (NSCLC) represents a significant challenge, constituting 85% of all diagnoses. The primary obstacles in treating NSCLC include overcoming resistance to front-line therapies and enhancing the effectiveness of immunotherapy treatments. Biocytogen is at the forefront of developing new treatments for NSCLC. By discovering fully human monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), and bispecific ADCs (bsADCs), we aim to target cancer cells directly or boost anti-tumor immune responses. Our innovative approach offers promising solutions in the fight against NSCLC. Join us in our mission to advance cancer treatment and bring hope to patients worldwide! #Biocytogen #Immunotherapy #CancerResearch #NSCLC #InnovationInHealthcare

Happy National Dog Day! 🐾 Let’s celebrate the love and joy our furry friends bring into our lives.  🐶❤️ #NationalDogDay

🌟 Dive into Innovation at Gene-ius Break Forum in South SF! 🌟 Join us on September 25th in South San Francisco for the Gene-ius Break Forum— a unique event where insightful speeches take the spotlight, complemented by complimentary food, drinks, and invaluable networking opportunities! These exciting presentations add immense value to this exceptional event. After the talks, savor delicious food and drinks while networking with industry leaders. Don’t miss this rare opportunity to gain insights, spark new ideas, and be part of something truly extraordinary—RSVP today! 🗓️ Date: Wednesday, September 25th · 4pm - 8pm PDT 📍 Location: Tower Place, 1 Tower Pl, South San Francisco, CA 94080 RSVP here: https://lnkd.in/eWHbVtwS #Biocytogen #HappyHour #SouthSF #Networking #Innovation #Biotech

🌟Exploring the Potential of CD40L Antagonists in Autoimmune Disease🔬 Exciting Developments in Autoimmune Therapy! CD40 ligand (CD40L), which is transiently expressed on activated T cells and is crucial for both antibody and cell-mediated immune responses, has been the focus of over 30 years of research aimed at developing effective inhibitors. Several CD40L antagonists currently in clinical trials have shown promising therapeutic benefits for both organ-specific and systemic autoimmune diseases, with the potential to impact a broader range of immune-mediated inflammatory conditions, including inflammatory bowel disease and rheumatoid arthritis. At Biocytogen, we're dedicated to advancing these developments. Our humanized mouse models of CD40L offer a crucial human genetic context for drug testing. Additionally, we've created fully human antibodies targeting CD40L with our proprietary RenMice platforms, driving the development of innovative therapies.💡Contact us to learn how our advanced products and services can enhance your research! B-hCD40L mice: https://lnkd.in/eeWwQaM3 B-hCD40/hCD40L mice: https://lnkd.in/eFd3sEmv Read more: https://lnkd.in/eNDkRkwA #AutoimmuneDisease #Immunotherapy #ClinicalTrials #HealthcareInnovation #Biotech

Unlock the Future of Immunotherapy with Humanized TLR7 and TLR8 Models Explore the potential of advanced immunotherapy for inflammatory diseases and cancer with our humanized TLR7 and TLR8 models. TLR7 and TLR8 are crucial in recognizing pathogen-associated molecular patterns (PAMPs) and triggering cytokine production for effective immune responses. Our B-hTLR8 and B-hTLR7/TLR8 mouse models offer a cutting-edge platform for evaluating therapeutic candidates targeting autoimmune diseases, viral infections, and cancer. With the ability to analyze in a human genetic context, these models offer crucial insights into the roles of TLR7 and TLR8 in disease progression and treatment efficacy. Contact us and explore how these models can drive your research forward! #Immunotherapy #CancerResearch #AutoimmuneDiseases #TLRModels #Biocytogen